2 Information about brentuximab vedotin
Marketing authorisation indication
2.1 Brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated 'for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The NHS list price of brentuximab vedotin is £2,500 per 50‑mg vial (excluding VAT; BNF online, accessed June 2020). Based on a mean of 6 cycles, the cost for an average patient is estimated at about £47,619, at list price. The company has a commercial arrangement. This makes brentuximab vedotin available to the NHS with a discount. The size of the discount is confidential. It is the company's responsibility to let relevant NHS organisations know details of the discount.